Castration-resistant Prostate Cancer Clinical Trial
— PROGNOSTICSOfficial title:
Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study
Researchers will test a new treatment for prostate cancer. This treatment uses an antibody tagged with a small amount of radioactive material. Researchers believe the new antibody might work better than those used before. In the first part of the study researchers will compare the new treatment to the old one on prostate cancer patients using very low doses, not strong enough to treat nor to cause strong adverse reactions. Each patient will eventually receive both treatments, but one at a time. The aim of the second part of the study is to find the best dose of the new treatment for patients. This means finding the dose that offers the most benefits with the fewest side effects. The performance of different prostate cancer diagnostic methods is also in scope of the study.
Status | Not yet recruiting |
Enrollment | 25 |
Est. completion date | June 2028 |
Est. primary completion date | June 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Consent form signed - Male patients with age > 18 years - Clinical indication for RLT with 177Lu-PSMA-I&T (progressive PSMA-positive mCRPC patients after androgen receptor signalling pathway inhibitor and taxan-based chemotherapy or patient unfit for chemotherapy) - Patients will be included in Phase Ia while being under active therapy with 177Lu-PSMA-I&T (SoC) and after they have completed the first two cycles of 177Lu-PSMA-I&T RLT - At least 3 measurable tumours on PSMA PET/CT (>1.5 cm) with sufficiently intense PSMA uptake (SUVmax>20) - ECOG Performance status: 0-1 - Blood parameters: a) Leucocytes = 3 G/L; b) Haemoglobin = 100 g/L; c) Thrombocytes = 100 G/L - Estimated glomerular filtration rate (eGFR) > 45 ml/min - Albumin > 25 g/L - ALT, AST, AP: = 5 times upper standard value - Bilirubin = 2 times upper standard value - For male patients who are not surgically sterilized (orchiectomy or vasectomy), appropriate contraceptive measures must be taken during RLT and until 4 months after completion of RLT. As acceptable contraceptive count sexual abstinence or double contraceptive methods: hormonal contraceptive (oral, transdermal, implants or injections) in combination with barrier methods (spiral, condom, diaphragm) Exclusion Criteria: - Prior PSMA-targeted RLT (except for the 2 first cycles in Part Ia) - PSMA-negative (or PSMA-negative / FDG-positive) disease - Known intolerance against DOTA, DOTAGA, urea-based analogues or against any of the components/formulation of 177Lu-PSMA-I&T or 161Tb-SibuDAB solutions. - Ongoing infection at the screening visit or a serious infection in the past 4 weeks - Administration of another investigational product in the last 60 days before Visit 1 Day 1 - Prior or planed administration of a therapeutic radiopharmaceutical during 8 half-lives of the used radio-pharmaceutical's radionuclide, also during the ongoing study - Any extensive radiotherapy involving bone marrow over the last 3 months before inclusion to the study - Chemotherapy in the last 4 weeks before inclusion - Any uncontrolled significant medical, psychiatric or surgical condition (active infection, unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension, poorly controlled diabetes mellitus [HbA1c = 9%], uncontrolled congestive heart disease, etc.) or laboratory findings that might jeopardize the patient's safety or that would limit compliance with the objectives and assessments of the study. Any mental conditions which prevent the patient from understanding the type, extent and possible consequences of the study and/or an uncooperative attitude from the patient. - Current history of any malignancy other than prostate cancer within 5 years of enrolment except for fully resected non-melanoma skin cancer |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Basel | Basel |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase Ia: Tumour absorbed dose | Comparison of median tumour absorbed dose, in Gy, after sequential injections of non-therapeutic test activity of 161Tb-SibuDAB and 177Lu-PSMA I&T in the same patients.
Tumour absorbed dose is obtained by SPECT/CT of head, thorax, abdomen and pelvis and represents the time integrated tumour activity (3 tumours per patient). To avoid carry-over effects, a period of at least 21 days will be allowed between the two consecutive test injections. |
3, 24, 48 and 168 hours after each injection | |
Primary | Phase Ib: Identification of the optimal biological dose of 161Tb-SibuDAB for mCRPC RLT | Identification of the optimal biological dose of 161Tb-SibuDAB, in GBq, for mCRPC RLT. The optimal maximum tolerated dose / biological dose will be the highest 161Tb-SibuDAB injected activity which elicits a clinically relevant adverse event grade G3 (according to CTCAE 5.0, ranging from G1 to G5 where G1 corresponds to mild AE and and G5 corresponds to AE related death) in maximal 1 patient per cohort / 1 patient in two cohorts. | baseline and 1 week, 2 weeks and 4 weeks after each injection. Long term: 6 and 12 months after RLT | |
Secondary | Phase Ia: Estimation of critical organ median absorbed doses | Estimation of critical organ (bone marrow, kidney, salivary gland) median absorbed doses after injection of a non-therapeutic test activity of 161Tb-SibuDAB and 177Lu-PSMA I&T in the same patients. Critical organ absorbed dose is obtained by SPECT/CT of head, thorax, abdomen and pelvis and represents the time integrated tumour activity (3 tumours per patient). Blood samples are collected at each timepoint to enable bone marrow dosimetry. | 3, 24, 48 and 168 hours after each injection | |
Secondary | Phase Ia: Estimation of the median tumour-to-critical organ absorbed dose ratios | Estimation of the median tumour-to-critical organ absorbed dose ratios after test activity injections of 161Tb-SibuDAB and 177Lu-PSMA-I&T in same patient. The potential therapeutic index will be calculated by take the simple ratio between the median tumour doses (Outcome 1) and the corresponding critical organ doses (Outcome 3) in each patient. | 3, 24, 48 and 168 hours after each injection | |
Secondary | Phase Ib: Cumulative median tumour and organ absorbed doses after 4 cycles of 161Tb-SibuDAB RLT | The median cumulative tumour absorbed dose will represent the 4-cycle summation of the median tumour absorbed dose after receiving the therapeutic injected activity of 161Tb-SibuDAB. This will be normalized to the injected activity (expressed as Gy/GBq). | 3, 24, 48 and 168 hours after each injection | |
Secondary | Phase Ib: Estimation of the "therapy index" for 161Tb-SibuDAB RLT. | Simple radios will be calculated between the cumulative median tumour absorbed dose and the cumulative median doses of different critical organs following completion of 161Tb-SibuDAB RLT. The "therapy index" will be identified as the lowest value for the calculated ratios. | 3, 24, 48 and 168 hours after each injection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00974311 -
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
|
Phase 3 | |
Active, not recruiting |
NCT03700099 -
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
|
Phase 2 | |
Completed |
NCT02124668 -
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
|
Phase 2 | |
Completed |
NCT01634061 -
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
|
Phase 1 | |
Completed |
NCT01338831 -
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT03652493 -
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
|
Phase 2 | |
Recruiting |
NCT04549207 -
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
|
Phase 4 | |
Active, not recruiting |
NCT03305224 -
The Combination Therapy With Ra-223 and Enzalutamide
|
Phase 2 | |
Active, not recruiting |
NCT04090528 -
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04070209 -
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
|
Phase 2 | |
Active, not recruiting |
NCT06193993 -
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
|
Phase 1 | |
Completed |
NCT02669771 -
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
|
||
Active, not recruiting |
NCT05084859 -
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03934164 -
Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO
|
||
Recruiting |
NCT03506997 -
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT03569280 -
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
|
Phase 1 | |
Enrolling by invitation |
NCT03356912 -
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
|
Phase 2 | |
Not yet recruiting |
NCT04148885 -
A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 |